Proposal to list orthopaedic implants and associated products supplied by Surgical Specialties (NZ) Ltd

Hospital devices Consultation Closed

What we’re proposing

PHARMAC is seeking feedback on a proposal to list a range of orthopaedic implants and associated products (“Orthopaedic Products”) supplied by Surgical Specialties (NZ) Limited (“Surgical Specialties”) on Section H Part III of the Pharmaceutical Schedule from 1 August 2018.

Consultation closes at 5pm on Friday, 6 July 2018 and feedback can be emailed to

What would the effect be?

This proposed agreement would supersede any existing DHB contracts with this supplier for the devices proposed for listing 1 August 2018, subject to consultation and approval by PHARMAC’s Board or delegate (“Agreement”).

The Agreement would provide consistent terms and conditions for these devices for all DHB purchases from the proposed date of listing on the Pharmaceutical Schedule.

PHARMAC estimates that the Surgical Specialties agreement would be cost neutral for DHBs, based on current usage.

DHBs would be able to continue to procure other suppliers’ ranges of Orthopaedic Products, as the Agreement would not be for sole supply.

DHBs would have access to educational services which would be tailored to suit the needs of the individual DHB Hospitals.

Who we think will be interested

  • Suppliers and Wholesalers
  • DHB Staff
    • Orthopaedic Surgeons
    • Theatre and Sterile Services personnel
    • Procurement and supply chain personnel

About the orthopaedic implants and associated products

The orthopaedic implants under this agreement are used to treat bone related injury or disease through surgical intervention. The associated products relate to the instruments or products required for preparation and/or adherence at the implant site, or physical manipulation of the implants required when undertaking the surgery.

Why we’re proposing this

In April 2016, PHARMAC released a request for proposal (“RFP”) for non-exclusive national agreements for the supply of orthopaedic implants and associated products to DHB hospitals.

The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

PHARMAC has been working with suppliers in order to seek provisional agreements and this is the latest proposals to arise from that process. We intend to consult on proposed agreements with other suppliers over the coming months.

Details about our proposal

PHARMAC has entered into a provisional Agreement with Surgical Specialties for a range of Orthopaedic Products that would result in listing 601 products on the Pharmaceutical Schedule from 1 August 2018.

A full list of the products has not been included in this consultation however we are making it available along with pricing information to appropriate DHB personnel.

DHBs would be able to continue to choose which Orthopaedic Products they procure.

The Agreement includes terms for training and education services to be provided by Surgical Specialties to DHB personnel on appropriate use of their medical devices, which is to be provided at times as agreed with individual DHBs.

The following information provides a summary of the brands and product ranges in the proposed agreement:







Anika Therapeutics Inc

Anika Monovisc

Connexicon Medical Ltd


Innovative Design Orthopaedics Ltd


Kinamed Incorporated


MicroPort Orthopedics, Inc.


Biolox Delta





Profemur Gladiator

Profemur L Classic

Profemur TL


Transcend Femoral Head

Neo Medical SA




THI Total Health Care Innovation


To provide feedback

Send us an email: by 5pm, 6 July 2018.

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.